Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer

S. K. Chambers, R. L. Chopyk, J. T. Chambers, P. E. Schwartz, T. P. Duffy

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy‐related leukemia. Cancer 64:2459–2461, 1989.

Original languageEnglish (US)
Pages (from-to)2459-2461
Number of pages3
Issue number12
StatePublished - Dec 15 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer'. Together they form a unique fingerprint.

Cite this